- Home
- KPRX vs FTEL Comparison
KPRX vs FTEL Comparison
Compare KPRX & FTEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- FTEL
- Stock Information
- Founded
- KPRX 1998
- FTEL 2007
- Country
- KPRX United States
- FTEL Australia
- Employees
- KPRX N/A
- FTEL N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- FTEL
- Sector
- KPRX Health Care
- FTEL
- Exchange
- KPRX Nasdaq
- FTEL Nasdaq
- Market Cap
- KPRX 9.2M
- FTEL 9.1M
- IPO Year
- KPRX N/A
- FTEL 2023
- Fundamental
- Price
- KPRX $2.15
- FTEL $0.81
- Analyst Decision
- KPRX Strong Buy
- FTEL
- Analyst Count
- KPRX 1
- FTEL 0
- Target Price
- KPRX $10.00
- FTEL N/A
- AVG Volume (30 Days)
- KPRX 53.1K
- FTEL 3.5M
- Earning Date
- KPRX 11-07-2025
- FTEL 11-17-2025
- Dividend Yield
- KPRX N/A
- FTEL N/A
- EPS Growth
- KPRX N/A
- FTEL N/A
- EPS
- KPRX N/A
- FTEL N/A
- Revenue
- KPRX N/A
- FTEL $5,200,138.00
- Revenue This Year
- KPRX N/A
- FTEL N/A
- Revenue Next Year
- KPRX N/A
- FTEL N/A
- P/E Ratio
- KPRX N/A
- FTEL N/A
- Revenue Growth
- KPRX N/A
- FTEL 16.42
- 52 Week Low
- KPRX $2.05
- FTEL $0.78
- 52 Week High
- KPRX $4.18
- FTEL $792.00
- Technical
- Relative Strength Index (RSI)
- KPRX 33.03
- FTEL 26.70
- Support Level
- KPRX $2.26
- FTEL $1.02
- Resistance Level
- KPRX $2.39
- FTEL $3.49
- Average True Range (ATR)
- KPRX 0.14
- FTEL 0.51
- MACD
- KPRX -0.02
- FTEL -0.17
- Stochastic Oscillator
- KPRX 16.03
- FTEL 1.22
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About FTEL Fitell Corporation
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.